Literature DB >> 30567247

Polyarticular arthropathy and encephalopathy in a 70-year-old woman.

Cameron Scott Lewis1,2, Rohen Skiba2,3, Eli Gabbay3,4.   

Abstract

A 70-year-old woman with a background of portopulmonary hypertension, managed with sildenafil and oral diuretics, and cirrhosis, presented with acute on chronic haemorrhoidal bleeding, iron deficiency anaemia and worsening right heart failure. She presented in a normal conscious and cognitive state. Management involved intravenous diuresis with frusemide and blood transfusion. She quickly begun to develop fever, severe polyarticular arthropathy and progressive encephalopathy. Analgesia was started and antibiotics administered for potential septic sources. Extensive investigations, including full septic screen and neurological imaging, revealed no explainable aetiology for her precipitous decline. She continued to have febrile episodes, worsening polyarticular arthropathy and progressive encephalopathy eventually becoming unresponsive. Given the severe polyarticular arthropathy knee aspiration was performed. Urate crystals were identified and intravenous hydrocortisone and colchicine were started. Within 2 days she achieved full resolution of her systemic, musculoskeletal and neurological symptoms. We propose this as a rare case of gout-induced encephalopathy. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  delirium; metabolic disorders; rheumatology

Mesh:

Year:  2018        PMID: 30567247      PMCID: PMC6301750          DOI: 10.1136/bcr-2018-227058

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study.

Authors:  David J Hunter; Michael York; Christine E Chaisson; Ryan Woods; Jingbo Niu; Yuqing Zhang
Journal:  J Rheumatol       Date:  2006-06-01       Impact factor: 4.666

2.  Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction.

Authors:  J Haorah; B Knipe; J Leibhart; A Ghorpade; Y Persidsky
Journal:  J Leukoc Biol       Date:  2005-10-04       Impact factor: 4.962

3.  Acute polyarticular gout presenting as delirium.

Authors:  Michael E Wilson; Siu-Hin Wan; Arthur Beyder; Thomas G Osborn; Thomas J Beckman
Journal:  J Clin Rheumatol       Date:  2013-06       Impact factor: 3.517

Review 4.  Passage of cytokines across the blood-brain barrier.

Authors:  W A Banks; A J Kastin; R D Broadwell
Journal:  Neuroimmunomodulation       Date:  1995 Jul-Aug       Impact factor: 2.492

Review 5.  Recognition and management of withdrawal delirium (delirium tremens).

Authors:  Marc A Schuckit
Journal:  N Engl J Med       Date:  2014-11-27       Impact factor: 91.245

6.  Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin.

Authors:  Jung-Yoon Choe; Geon Ho Lee; Seong-Kyu Kim
Journal:  J Rheumatol       Date:  2010-12-15       Impact factor: 4.666

7.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

8.  [Gouty encephalopathy: myth or reality?].

Authors:  P Alla; P Carli; G Cellarier; J F Paris; A Chagnon
Journal:  Rev Med Interne       Date:  1997       Impact factor: 0.728

9.  CSF biomarkers in delirium: a systematic review.

Authors:  Roanna J Hall; Leiv Otto Watne; Emma Cunningham; Henrik Zetterberg; Susan D Shenkin; Torgeir Bruun Wyller; Alasdair M J MacLullich
Journal:  Int J Geriatr Psychiatry       Date:  2017-06-06       Impact factor: 3.485

Review 10.  Risk factors for incident delirium among older people in acute hospital medical units: a systematic review and meta-analysis.

Authors:  Suman Ahmed; Baptiste Leurent; Elizabeth L Sampson
Journal:  Age Ageing       Date:  2014-03-06       Impact factor: 10.668

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.